List of Binosto drug patents

Binosto is owned by Ascend Theraps Us.

Binosto contains Alendronate Sodium.

Binosto has a total of 3 drug patents out of which 0 drug patents have expired.

Binosto was authorised for market use on 12 March, 2012.

Binosto is available in tablet, effervescent;oral dosage forms.

The generics of Binosto are possible to be released after 05 December, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7964212 ASCEND THERAPS US Effervescent compositions comprising phosphonates and methods related thereto
Mar, 2023

(a month from now)

US7488496 ASCEND THERAPS US Effervescent compositions comprising bisphosphonates and methods related thereto
Aug, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195 ASCEND THERAPS US Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Dec, 2031

(8 years from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in